Diabetes & Obesity Research

High-Sensitivity ELISA Kits for GLP-1 & Metabolic Peptide Research

BMA Biomedicals offers a comprehensive portfolio of high-sensitivity ELISA kits designed for the accurate quantification of therapeutic peptides and incretin-based drugs used in metabolic disease research. Developed to deliver exceptional sensitivity, specificity, and reproducibility, these assays support pharmacokinetic studies, drug development, biomarker analysis, and translational research across diabetes, obesity, and metabolic disorders.

The portfolio includes assays for leading GLP-1 receptor agonists, dual and triple agonists, and next-generation peptide therapeutics.

To learn more about the science behind these therapies and the latest advances in metabolic health, click the link of our Blogs here below and explore the Diabetes & Obesity Research section.

Blogs

Monoclonal anti-Porcine Antibodies

Here at BMA, we develop antibodies specifically designed for use with porcine tissues, recognizing the crucial role this species plays in animal models and in studying diseases impacting human health. Our aim is to provide a comprehensive range of antibodies to support your assessment of veterinary tissue samples.

To learn more about BMA Biomedicals' portfolio of porcine tissue monoclonal antibodies, click the link of our blogs here below and explore the Monoclonal Anti-Porcine Antibodies section.

Blogs

About us

At BMA, teamwork is at the heart of everything we do, ensuring collaboration and innovation.

Find out more about our company.

Company